Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.

[1]  S. Iida,et al.  Induction of cell death in adult T-cell leukemia cells by a novel IκB kinase inhibitor , 2006, Leukemia.

[2]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[3]  Huan Yang,et al.  The Akt/PKB pathway: molecular target for cancer drug discovery , 2005, Oncogene.

[4]  J. Brady,et al.  Activated AKT regulates NF-κB activation, p53 inhibition and cell survival in HTLV-1-transformed cells , 2005, Oncogene.

[5]  C. Proud,et al.  Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2). , 2005, The Biochemical journal.

[6]  Suzanne F. Jones,et al.  A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors , 2005 .

[7]  Paul Tempst,et al.  Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis , 2005, Cell.

[8]  Yang Yang,et al.  Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-κB signal pathways , 2005, Molecular Cancer Therapeutics.

[9]  G. Laurent,et al.  Antileukemic activity of rapamycin in acute myeloid leukemia. , 2005, Blood.

[10]  M. Clement,et al.  LY294002 and rapamycin co‐operate to inhibit T‐cell proliferation , 2005, British journal of pharmacology.

[11]  L. Larizza,et al.  The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia , 2005, Leukemia & lymphoma.

[12]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[13]  D. Guertin,et al.  Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.

[14]  Peter J Houghton,et al.  Lost in translation: dysregulation of cap-dependent translation and cancer. , 2004, Cancer cell.

[15]  H. Koeffler,et al.  HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. , 2004, Molecular cancer therapeutics.

[16]  H. Koeffler,et al.  Proteasome inhibitor PS‐341 down‐regulates prostate‐specific antigen (PSA) and induces growth arrest and apoptosis of androgen‐dependent human prostate cancer LNCaP cells , 2004, Cancer science.

[17]  M. Carroll,et al.  Survival of acute myeloid leukemia cells requires PI3 kinase activation. , 2003, Blood.

[18]  C. Bucana,et al.  Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  M. Yamakuchi,et al.  Phosphoinositide-3 kinase-PKB/Akt pathway activation is involved in fibroblast Rat-1 transformation by human T-cell leukemia virus type I tax , 2001, Oncogene.

[20]  M. Tomonaga,et al.  A new G‐CSF‐supported combination chemotherapy, LSG15, for adult T‐cell leukaemia‐lymphoma: Japan Clinical Oncology Group Study 9303 , 2001, British journal of haematology.

[21]  C. Sawyers,et al.  The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Downward,et al.  Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3‐kinase , 1998, The EMBO journal.

[23]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[24]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[25]  Lewis C Cantley,et al.  PI3K: Downstream AKTion Blocks Apoptosis , 1997, Cell.

[26]  M. Tomonaga,et al.  An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[27]  M. Yoshida,et al.  Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[28]  K. Nagata,et al.  Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. , 1981, Proceedings of the National Academy of Sciences of the United States of America.